ライフサイエンスコーパス: portosystemic shunt

1 be referred for to transjugular intrahepatic portosystemic shunt.

2 oes not preclude the creation of nonsurgical portosystemic shunt.

3 ion or stenosis and the presence of a patent portosystemic shunt.

4 ter placement of a transjugular intrahepatic portosystemic shunt.

5 erance of liver to warm ischemia injury with portosystemic shunt.

6 is increase was significantly reversed after portosystemic shunt.

7 Five had variceal bleeding, and 2 had portosystemic shunts.

8 , liver transplants, choledocholithiasis, or portosystemic shunts.

9 ctive placement of transjugular intrahepatic portosystemic shunts.

10 r, eNOS (-/-) mice did develop a substantial portosystemic shunt (0.33% +/- 0.005% vs 84.53% +/- 0.19

11 2 +/- 0.003 vs 0.227 +/- 0.005 mL/min/g) and portosystemic shunt (0.47% +/- 0.01% vs 84.13% +/- 0.09%

12 Two patients had an extrahepatic portosystemic shunt, 17 had a portacaval shunt [subdivid

13 ophylaxis group was less likely to require a portosystemic shunt (6% vs 15%, p < 0.001) with no diffe

14 band ligation and transjugular intrahepatic portosystemic shunt, almost every acute variceal bleed c

15 traindications of transjugular intra-hepatic portosystemic shunt and for the treatment of gastro-esop

16 evaluate race as a predictor of undergoing a portosystemic shunt and LT and of dying in the hospital.

17 th vehicle, JWH-015 significantly alleviated portosystemic shunting and mesenteric vascular density i

18 s alternative treatment options to operative portosystemic shunts and devascularization procedures.

19 Despite these innovations, portosystemic shunts and esophagogastric devascularizati

20 us-1, previous LT, transjugular intrahepatic portosystemic shunt, and acute dialysis at LT.

21 lume paracenteses, transjugular intrahepatic portosystemic shunts, and implanted drainage devices.

22 ement therapy, and transjugular intrahepatic portosystemic shunting are discussed.

23 Large spontaneous portosystemic shunts are associated significantly with m

24 Transjugular intrahepatic portosystemic shunts are frequently used in patients wit

25 be successfully used as a bridge to surgical portosystemic shunting, as well as liver transplantation

26 Congenital extrahepatic portosystemic shunt (CEPS) or Abernethy malformation is

27 e hepatocytes after liver warm ischemia with portosystemic shunt, compared with liver ischemia withou

28 Congenital portosystemic shunts (CPSS) are rare vascular malformati

29 rum samples from dogs with either congenital portosystemic shunts (cPSS, n = 24) or high serum liver

30 creased patency at transjugular intrahepatic portosystemic shunt creation.

31 Ppv), abdominal aortic blood flow (Qao), and portosystemic shunt determined 2 weeks later.

32 The indications for and the results of portosystemic shunts done in the authors' institution si

33 Portosystemic shunt enhances the tolerance of liver to w

34 Liver disease or portosystemic shunting enhances th e sensitivity to endo

35 Spontaneous portosystemic shunts greater than 10 mm in diameter, ide

36 All extrahepatic portosystemic shunts, H-type portal-caval, portohepatic,

37 Transjugular intrahepatic portosystemic shunt has become an accepted intervention

38 g and placement of transjugular intrahepatic portosystemic shunts, have improved preoperative assessm

39 modalities such as transjugular intrahepatic portosystemic shunting, hemodialysis, and in some cases,

40 paracentesis with transjugular intrahepatic portosystemic shunt in the management of refractory asci

41 iography, which disclosed virtually complete portosystemic shunting in Fut2(-/-)(high) mice, discrete

42 c shunting in Fut2(-/-)(high) mice, discrete portosystemic shunting in Fut2(-/-)(low) mice, and no sh

43 ler hepatocyte size is the result of massive portosystemic shunting in null animals.

44 ocumented the frequency of large spontaneous portosystemic shunts in patients with moderate or severe

45 Although transjugular intrahepatic portosystemic shunt insertion (TIPS) is indicated for th

46 A transjugular intrahepatic portosystemic shunt is indicated when control of the ref

47 scularization with transjugular intrahepatic portosystemic shunting may also be considered for transp

48 scularization with transjugular intrahepatic portosystemic shunting may be considered for selected pa

49 Transjugular intrahepatic portosystemic shunts may be helpful in the treatment of

50 amics, presence of CB receptors, severity of portosystemic shunting, mesenteric vascular density, vas

51 Conclusion The presence of spontaneous portosystemic shunts on CT images in patients with cirrh

52 outflow obstruction classically treated with portosystemic shunts or liver transplantation.

53 A preemptive transjugular intrahepatic portosystemic shunt (p-TIPS) has been shown to improve s

54 ssion (pre-emptive transjugular intrahepatic portosystemic shunt: p-TIPS) increases the survival of h

55 Early transjugular intrahepatic portosystemic shunts placed in highly selected patients

56 vein embolization, transjugular intrahepatic portosystemic shunt placement, balloon retrograde transv

57 beta-blockers and transjugular intrahepatic portosystemic shunt placement.

58 The transjugular intrahepatic portosystemic shunt procedure is an effective interventi

59 who underwent the transjugular intrahepatic portosystemic shunt procedure.

60 ation or undergoing transvenous intrahepatic portosystemic shunt procedures.

61 ated by the presence of congenitally present portosystemic shunt (PSS), which resulted in markedly el

62 l and biochemical features of the congenital portosystemic shunt (PSS).

63 ic artery flow, mesenteric vascular density, portosystemic shunting (PSS), intrahepatic angiogenesis,

64 lar in preclinical research, have congenital portosystemic shunts (PSS) that allow venous blood to en

65 urements, including portal pressure (PP) and portosystemic shunts (PSS), and collected tissues for hi

66 A modified transjugular intrahepatic portosystemic shunt puncture set was introduced from the

67 t2(-/-) mice is dominated by consequences of portosystemic shunting resulting in microcirculatory dis

68 150 min liver warm ischemia with or without portosystemic shunt (splenic-caval shunt).

69 Spontaneous portosystemic shunts (SPSSs) are common among patients w

70 Large spontaneous portosystemic shunts (SPSSs) have been previously sugges

71 The impact of spontaneous portosystemic shunts (SPSSs) on natural history of cirrh

72 d to the consequent formation of spontaneous portosystemic shunts (SPSSs), leading to complications r

73 al indications for transjugular intrahepatic portosystemic shunting, such as those with refractory as

74 ve been treated by transjugular intrahepatic portosystemic shunt, surgical exploration, or peritoneov

75 to the systemic circulation, which is called portosystemic shunt syndrome.

76 Transjugular intrahepatic portosystemic shunt (TIPS) and surgical distal splenoren

77 lity and safety of transjugular intrahepatic portosystemic shunt (TIPS) as a treatment for BCS with d

78 thoracentesis and transjugular intrahepatic portosystemic shunt (TIPS) as second-line therapeutic op

79 ter placement of a transjugular intrahepatic portosystemic shunt (TIPS) correlates with the absence o

80 ailure (ELF) after transjugular intrahepatic portosystemic shunt (TIPS) creation in patients with cir

81 Background Transjugular intrahepatic portosystemic shunt (TIPS) creation is an accepted treat

82 d complications of transjugular intrahepatic portosystemic shunt (TIPS) creation performed by using a

83 ents who underwent transjugular intrahepatic portosystemic shunt (TIPS) creation, regardless of left

84 Background Transjugular intrahepatic portosystemic shunt (TIPS) dysfunction in patients with

85 and bare stent in transjugular intrahepatic portosystemic shunt (TIPS) for cirrhotic portal hyperten

86 ibe the results of transjugular intrahepatic portosystemic shunt (TIPS) for the management of VOD aft

87 Recently, transjugular intrahepatic portosystemic shunt (TIPS) has been compared with ET in

88 the placement of a transjugular intrahepatic portosystemic shunt (TIPS) has been reported in up to 10

89 on human patients, transjugular intrahepatic portosystemic shunt (TIPS) has been worldwide considered

90 ients treated with transjugular intrahepatic portosystemic shunt (TIPS) have lower rebleeding rates c

91 Implantation of a transjugular intrahepatic portosystemic shunt (TIPS) improves survival in patients

92 s, and efficacy of transjugular intrahepatic portosystemic shunt (TIPS) in a series of patients with

93 Transjugular intrahepatic portosystemic shunt (TIPS) in patients with portal hyper

94 cacy and safety of transjugular intrahepatic portosystemic shunt (TIPS) in this population are unknow

95 opathy (HE) after Trans-jugular intrahepatic portosystemic shunt (TIPS) is a common clinical problem.

96 The transjugular intrahepatic portosystemic shunt (TIPS) is an important treatment for

97 Transjugular intrahepatic portosystemic shunt (TIPS) is now a standard for the tre

98 Transjugular intrahepatic portosystemic shunt (TIPS) is one of the main treatment

99 Transjugular intrahepatic portosystemic shunt (TIPS) is performed to treat some co

100 Transjugular intrahepatic portosystemic shunt (TIPS) is used in the management of

101 ansplantation, and transjugular intrahepatic portosystemic shunt (TIPS) on patient selection and outc

102 The effects of transjugular intrahepatic portosystemic shunt (TIPS) on portal hemodynamics, esoph

103 ty and efficacy of transjugular intrahepatic portosystemic shunt (TIPS) performed semiemergently and

104 Elective transjugular intrahepatic portosystemic shunt (TIPS) placement can worsen cognitiv

105 disease underwent transjugular intrahepatic portosystemic shunt (TIPS) placement for control of vari

106 hosis and ascites, transjugular intrahepatic portosystemic shunt (TIPS) placement improves control of

107 on with or without transjugular intrahepatic portosystemic shunt (TIPS) placement in patients who are

108 Transjugular intrahepatic portosystemic shunt (TIPS) placement is effective in the

109 w before and after transjugular intrahepatic portosystemic shunt (TIPS) placement.

110 nts undergoing the transjugular intrahepatic portosystemic shunt (TIPS) procedure in patient groups w

111 cations related to transjugular intrahepatic portosystemic shunt (TIPS) stents found in the portal ve

112 converting failed transjugular intrahepatic portosystemic shunt (TIPS) to distal splenorenal shunt (

113 canalization (PVR)-transjugular intrahepatic portosystemic shunt (TIPS) to potentiate LT.

114 ognosis of salvage transjugular intrahepatic portosystemic shunt (TIPS) using covered stents for refr

115 Additional transjugular intrahepatic portosystemic shunt (TIPS) was created to facilitate the

116 The transjugular intrahepatic portosystemic shunt (TIPS) was developed in the 1980s fo

117 ble on the role of transjugular intrahepatic portosystemic shunt (TIPS) with covered stents in patien

118 atients undergoing transjugular intrahepatic portosystemic shunt (TIPS).

119 for creation of a transjugular intrahepatic portosystemic shunt (TIPS).

120 ainly treated with transjugular intrahepatic portosystemic shunt (TIPS).

121 ant and five had a transjugular intrahepatic portosystemic shunt (TIPS).

122 paracentesis, and transjugular intrahepatic portosystemic shunt (TIPS)], but refractory hydrothorax

123 ility, before/after transvenous intrahepatic portosystemic shunting (TIPS), and before/after yogurt t

124 catheter-directed thrombolysis, transjugular portosystemic shunting (TIPS), and liver transplantation

125 asty/thrombolysis, transjugular intrahepatic portosystemic shunting (TIPS), and orthotopic liver tran

126 Transjugular intrahepatic portosystemic shunts (TIPS) are a recent innovation in t

127 Transjugular intrahepatic portosystemic shunts (TIPS) are sometimes used to reduce

128 te the efficacy of transjugular intrahepatic portosystemic shunts (TIPS) for the treatment of chronic

129 after creation of transjugular intrahepatic portosystemic shunts (TIPS) has been attributed to hemol

130 re of infection of transjugular intrahepatic portosystemic shunts (TIPS) has not been described previ

131 Transjugular intrahepatic portosystemic shunts (TIPS) have widened the use of port

132 ts with the use of transjugular intrahepatic portosystemic shunts (TIPS) in the treatment of these pa

133 Transjugular intrahepatic portosystemic shunts (TIPS) is a second-line treatment b

134 ectasia (GVE), to transjugular intrahepatic portosystemic shunts (TIPS) is not known.

135 Transjugular intrahepatic portosystemic shunts (TIPS) lower portal pressure and ha

136 Transjugular intrahepatic portosystemic shunts (TIPS) may worsen liver function an

137 ver the ability of transjugular intrahepatic portosystemic shunts (TIPS) to increase survival times o

138 ver the ability of transjugular intrahepatic portosystemic shunts (TIPS) to increase survival times o

139 linical utility of transjugular intrahepatic portosystemic shunts (TIPS) vis-a-vis total paracentesis

140 (CT) angiograms of transjugular intrahepatic portosystemic shunts (TIPS), helical CT angiography was

141 ing the patency of transjugular intrahepatic portosystemic shunts (TIPS).

142 ng procedures (upper endoscopy, transjugular portosystemic shunt [TIPS], hemodialysis, and liver tran

143 Models described in rats using portosystemic shunts to achieve total ischemia have been

144 previously placed transjugular intrahepatic portosystemic shunt underwent successful liver transplan

145 andomized trial of transjugular intrahepatic portosystemic shunt using covered stents and another pil

146 with subsequent guidewire snaring to perform portosystemic shunting via femoral access.

147 A transjugular intrahepatic portosystemic shunt was created in 14 young swine (weigh

148 Portosystemic shunting was demonstrated by portal angiog

149 Portosystemic shunting was shown by radiological methods

150 tes, the adjusted odds ratios of receiving a portosystemic shunt were 0.37 (95% CI: 0.27-0.51) and 0.

151 raindication for a transjugular intrahepatic portosystemic shunt who received either device implantat

152 l stenosis and the presence of a spontaneous portosystemic shunt whose successful endovascular treatm

153 ugs+endoscopy, the placement of transjugular portosystemic shunt within 72 hours of admission (pre-em